2 publications

• Published Subscription 10 Jan 2022

  Covid-19 Associated Mucormycosis: Urgency To Reconsider The Uncontrolled Use Of Prophylactic Drugs

  By Chandani Kamble, Vikas Kamble, Sharad Kamble, Prakash Kamble, Rani Kamble

  Abstract: Mucormycosis, a lethal mycosis, has affected hundreds of COVID-19 sufferers in India. Mucormycosis, previously known as zygomycosis, is due to the diverse fungi that belong to the family "Mucorales." These molds are normally determined in soil, air, and damp partitions and often colonize oral mucosa, nose, paranasal sinuses, and throat. The pathophysiological results of diabetes mixed with the intense inflammatory surge in COVID-19 and steroid remedy weaken a person's immunity …

  Published in Research and Reviews: A Journal of Medicine · Vol. 11, Issue 3, 2021 · pp. 12–17 Read article →

• Published Subscription 5 Jan 2022

  Novel plasma therapy for covid-19: A Perspective

  By Chandani Kamble, Sharad Kamble, Pragati Pandit

  Abstract: Coronavirus disease (COVID-19) is an induced disease caused by the coronavirus-19 that causes acute respiratory syndrome (SARS COVID-19). In the month of December 2019, the first case was recorded in Wuhan, China. No specific medications have yet been approved for their treatment; convalescent plasma therapy is projected to boost the survival rate. Early in the twentieth century, convalescent plasma therapy was developed. Convalescent plasma therapy is widely utilized around the …

  Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 10, Issue 3, 2021 · pp. 30–34 Read article →